Consolidated Statements of Operations - USD ($)		12 Months Ended
		Mar. 31, 2020	Mar. 31, 2019	Mar. 31, 2018
Operating expenses:
Research and development	[1]	$ 192,560,000	$ 222,607,000	$ 116,832,000
General and administrative	[2]	82,327,000	42,219,000	24,231,000
Total operating expenses		274,887,000	264,826,000	141,063,000
Interest expense		11,222,000	8,821,000	2,046,000
Loss on extinguishment of debt		4,851,000	0	0
Interest expense (related party)		1,441,000	0	0
Interest income		(2,552,000)	(881,000)	0
Other (income) expense, net		(1,621,000)	309,000	(67,000)
Total loss before income taxes		(288,228,000)	(273,075,000)	(143,042,000)
Income tax expense		761,000	476,000	213,000
Net loss		$ (288,989,000)	$ (273,551,000)	$ (143,255,000)
Net loss per common share — basic and diluted (in USD per share)		$ (3.37)	$ (4.09)	$ (2.41)
Weighted average common shares outstanding — basic and diluted (in shares)		85,839,303	66,910,060	59,520,747

[1] Includes $76, $2,575 and $4,537 of costs allocated from the Company’s former majority shareholder during the years ended March 31, 2020, 2019 and 2018, respectively. Also includes share-based compensation expense (see Note 10).

[2] Includes $617, $2,873 and $4,182 of costs allocated from the Company’s former majority shareholder during the years ended March 31, 2020, 2019 and 2018, respectively. Also includes share-based compensation expense (see Note 10).